Zafgen to take severe obesity candidate into Phase II with $33M in new funds
This article was originally published in Scrip
Executive Summary
Zafgen, a Cambridge, Massachusetts start-up developing novel obesity therapeutics, has raised $33 million in a third venture round as it prepares to take its lead compound, ZGN-433, for severely obese patients, into a Phase II trial and show that it is the first pharmaceutical alternative to bariatric surgery. Zafgen also hopes to show that ZGN-433, by changing the way the body metabolises fat through a novel mechanism, has additional benefits, particularly in normalising cardiovascular risk.